摘要
目的分析肝动脉化疗栓塞术(TACE)联合射频消融术(RFA)治疗无法手术的肝细胞癌(HCC)患者的疗效及预后因素。方法选择我院无法手术切除或不愿手术的肝细胞癌患者60例,随机分成TACE组(n=30)和TACE联合RFA治疗组(n=30),观察两组疗效、不良反应和生存时间。结果 TACE组的有效率为50.0%,联合治疗组为86.7%,组间差异有统计学意义(P<0.05);中位生存时间分别为13个月和18个月(P<0.05)。联合治疗组1年和2年总生存率分别为73.3%(22/30)和20.0%(6/30),而TACE组为56.7%(17/30)和6.7%(2/30),组间差异均有统计学意义(P<0.05)。联合组谷丙转氨酶升高发生率53.3%(16/30)高于TACE组46.7%(14/30),但差异无统计学意义(P>0.05)。结论 TACE联合RFA治疗无法手术的肝细胞癌可提高患者生存率,延长患者的生存期;肿瘤多发、肿瘤毗邻肝脏脏面、肿瘤最大直径等3项指标是影响患者预后的危险因素。
Objective To analyze the efficacy of transcatheterarterial chemoembolization （TACE ） combined with radi-ofrequency ablation （RFA） for inoperable hepatocellular carcinoma （HCC） and the prognostic factors. Methods A toal of 60 cases of HCC patients who were unable or unwilling to carry out surgery were included in this study. Patients were divided into two groups, TACE group （n=30） and the TACE＋RFA combined group （n=30）. All patients were given TACE one or several times, while the patients in the TACE＋RFA group were added with RFA 1-2 weeks after TACE treatment. Observe the curative effects, adverse reactions and the survival time. Results The total effective rate was 50.0%and 86.7%respec-tively in TACE group and TACE＋RFA group, with statistical difference between the two groups （P〈0.05） . The median survival time were 13 months and 18 months respectively in TACE group and TACE＋RFA group （P〈0.05）. The 1-and 2-year survival rates were respectively 73.3%（22/30） and 20.0%（6/30） in the TACE＋RFA group, but were respectively 56.7%（17/30） and 6.7%（2/30） in the TACE group （P〈0.05）. The incidence of rise of glutamic-pyruvic transaminase in the TACE＋RFA group was 53.3%（16/30）, higher than in the TACE group [46.7%（14/30）], but the difference had no statistical significance （P〈0.05）. Conclusion TACE combined with RFA could significantly increase the survival rate and prolong survival period of patients. The multiple lesions, the maximum diameter, and the location of tumors adjacent the liver vis-ceral surface are risk factors affecting prognosis.
出处
《肿瘤药学》
CAS
2015年第5期379-383,共5页
Anti-Tumor Pharmacy
关键词
肝细胞癌
预后因素
TACE
RFA
TACE
RFA
Hepatocellularcarcinoma
Impactfactors
